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treatment effects using multivariate meta-analyses. Results: Given the variation 
in analysis populations and timing of outcome assessment across RCTs, a limited 
number of studies were considered sufficiently similar for meta-analyses. For NP, 
a positive relationship between microbiological eradication and cure (correlation 
coefficient of 0.84; 95%CI 0.07, 0.98; 5 studies) and a negative relationship between 
eradication and mortality (-0.86; 95%CI -0.97, -0.34; 7 studies) were observed. For 
cIAI, clinical outcome was used as a proxy measure for microbiological eradication, 
but no correlation with mortality was identified. No relationship was observed for 
cUTI either. ConClusions: Relationships between treatment effects in terms of 
eradication and clinical cure and between eradication and mortality were identified 
for NP. For cIAI and cUTI, the relationship between microbiologic eradication and 
treatment effects is unclear based on available study level RCT evidence. Given the 
great variation between studies and several uncertain findings, evaluations using 
patient level data are recommended.
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objeCtives: Human Immunodeficiency Virus (HIV) has become a chronic man-
ageable disease after the advent of combination antiretroviral therapy (ART). Since 
launching of ART, the numbers of patients enrolled in to ART are increasing in 
developing countries like India. In this study we aim to analyze clinical and immu-
nological outcomes of ART in a community care hospital. Methods: A retrospec-
tive cohort study was conducted by including 800 ART naive HIV infected adult 
patients initiated on ART. All patients survived in ART centre at Mysore, India for 12 
months from January 2013 to January 2014 were included. Parameters like weight, 
hemoglobin, WHO clinical stage and CD4 count were collected from medical records 
before initiation and after completion of 12 months ART. Outcomes of ART were 
analyzed by paired T- test using SPSS version 21. Results: A statistically signifi-
cant improvement was observed for weight [53.9 (11.9) to 58.2 (32.6) kg; P = 0.002] 
and CD4 count [206.6 (177.4) to 331.1 (220.5); P = 0.001] at the end of 12 months of 
ART treatment. Whereas, marginal improvement in hemoglobin [11.94 (4.3) to 11.98 
(5.7) g%; P = 0.91] was observed, though it was not statistically significant. Also 
observed a significant increase in percentage of patients in WHO clinical stage I 
(64-82%) and decrease in number of patients in stages II (13-14%), III (5-2%) and IV 
(18-12%). ConClusions: The improvement in weight and CD4 count are indirect 
parameters of > 95% medication adherence and of sustained viral suppression. The 
optimal outcome would have been all patients in WHO clinical stage I or II and none 
in III and IV, but in this study 2% and 12% of patients continued to be in stage III and 
IV respectively. This may be due to development of opportunistic infections such as 
tuberculosis which is endemic in India.
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objeCtives: Oritavancin (ORI) is a lipoglycopeptide with bactericidal activity 
against Gram-positive bacteria including MRSA. This analysis evaluated efficacy 
and hospital length of stay of ORI for patients with acute bacterial skin and skin 
structure infections (ABSSSI) who received care in the SOLO program in the US 
and Eastern Europe. Methods: SOLO I and II were identically-designed compara-
tive, multicenter, double-blind, randomized studies to evaluate the efficacy and 
health care resource utilization (HRU) of single 1200 mg dose IV ORI versus 7-10 
days of twice-daily intravenous (IV) vancomycin (VAN) for the treatment of ABSSSI. 
SOLO protocols were amended (Amendment 2) to allow outpatient treatment at the 
investigator’s discretion. Efficacy and HRU of treatment were assessed in inpatient 
and outpatient settings. Efficacy for the European Medicines Agency (EMA) was 
investigator-assessed clinical cure 7-14 days after end of treatment. HRU endpoints 
were hospitalization rate and length of stay (LOS) in days if the patient was hos-
pitalized. Results: In the combined studies, 1959 patients were in the modified 
intent-to-treat (mITT) population; 1,172 patients (60%) received a portion of their 
care in as inpatients; 202 patients were treated in Eastern European countries (EUC: 
Russian Federation, Romania and Ukraine) and 1,165 were treated in the US. Clinical 
cure rates were similar for ORI and VAN in both regions (86.1% and 84.2% in EUC, 
80.6% and 77.9% in the US. The average LOS (ALOS) in the EUC was longer than in 
the US (14.9 and 14.7 vs. 6.0 and 6.4 days). ConClusions: Clinical cure rates at PTE 
were similar between ABSSSI patients who received a single dose of ORI or 7-10 days 
of VAN in SOLO, but the ALOS in the US was considerably shorter than in Eastern 
Europe. Using oral or long-acting antibiotic treatments may reduce the numbers of 
inpatient IV antibiotic administrations, which has been associated with reduced 
LOS in other studies.
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objeCtives: Vaccination has proven to be an efficient preventive strategy against 
influenza infection. Each year, two genetically distinct influenza B lineages co-
circulate. Current trivalent influenza vaccines (TIVs) contain only one influenza 
B and two influenza A strains, but vaccine mismatch are frequent due to the 
difficulty to predict which B lineage will predominate during the next epidemic. 
objeCtives: Inadequate control over emesis during cancer chemotherapy can 
adversely affect patient’s quality of life, delay the subsequent chemotherapy cycle 
and may lead to poor adherence to treatment. This study was conducted to assess 
appropriateness of anti-emetics use in the management of chemotherapy induced 
nausea and vomiting. Methods: A prospective observational study was conducted 
for a period of 6 months at private cancer hospital. Medical records of the patients 
on chemotherapy were reviewed and patients were interviewed to assess the pre-
scribing pattern of anti-emetics and its appropriateness. Chemotherapy regimen 
and given anti-emetics for each patient were recorded and reviewed with respect 
to National Comprehensive Cancer Network (NCCN) guidelines for anti-emesis to 
ensure the appropriateness of drug use. Results: Of 346 patients’ record reviewed, 
majority (74%) of them were prescribed with drugs which are highly emetogenic 
followed by 17% of them with moderately emetogenic and 9% of them with low 
emetogenic potential. Unlike 30% of patients who were added with NK-1 recep-
tor antagonist (NK1RA) either in oral or intravenous formulation, majority (n= 184, 
70.76%) of the patients receiving highly emetogenic regimen were placed on com-
bination of 5-HT3 antagonist and corticosteroids without adding NK1RA for pre-
vention of acute and delayed emesis. Majority patients (64%) receiving moderately 
emetogenic regimen were prescribed with combination of 5-HT3 antagonist and 
corticosteroids and remaining received combination of metoclopramide with cor-
ticosteroids. Most of the patients (82%) receiving low emetogenic regimen were 
prescribed with combination of metoclopramide and corticosteroids and remain-
ing were prescribed with 5-HT3 antagonist and corticosteroid. Over all, selection of 
anti-emetic regimen was inappropriate for 32% (n= 112) patients. Dosage, frequency 
and duration of anti-emetic use were inappropriate in 18%, 38% and 8% respec-
tively. ConClusions: Most of the patients received same anti-emetic regimen for 
highly emetogenic and moderately emetogenic agents. Cost was the limiting factor 
to choose an appropriate anti-emetic regimen.
INfeCtIoN – Clinical outcomes Studies
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objeCtives: Cobicistat, a CYP3A inhibitor, is a novel, alternative pharmacoen-
hancer to ritonavir. A fixed-dose combination once-daily formulation that contains 
darunavir and cobicistat has been developed to simplify dosing and to enhance 
patient convenience. This analysis compared the virological response of a cobi-
cistat-boosted versus a ritonavir-boosted darunavir QD regimen by testing for non-
inferiority. Methods: Patient level data on 800mg QD darunavir treatment from 3 
phase 3 trials (GS-216-0130, TMC114-C211, TMC114-C229) were combined for analy-
sis of virological response at Week 48, using the Snapshot algorithm methodology. 
Patients were HIV-1-infected treatment-naïve or -experienced with no darunavir 
resistance-associated mutations at baseline. The non-inferiority margin was set 
at 0.531 on the odds-ratio (OR) scale, which corresponded to a 12% non-inferiority 
margin on the risk-difference scale, assuming an 80% response rate.  Multiple logis-
tic regression was used to adjust for differences in baseline patient characteristics 
(age, gender, race, baseline CD4+ T-cell counts, baseline HIV-1 RNA, HIV disease 
status, and previous antiretroviral use) and level of darunavir treatment adher-
ence. A sensitivity analysis was performed on data from patients with viral load<50 
copies/mL according to time to loss-of-virological response (TLOVR) algorithm at 
week 48. Results: Treatment with darunavir/cobicistat(800/150mg QD, n=313) was 
non-inferior to darunavir/ritonavir (800/100mg QD, n=637). Unadjusted virological 
response rates were 81% and 78%, respectively. The adjusted odds ratio [95% CI] 
for virological response comparing darunavir/cobicistat with darunavir/ritonavir at 
week 48 was 0.878 [0.576, 1.339] (Snapshot). The 95% CI lower boundary was above 
the defined non-inferiority margin. The sensitivity analysis gave similar results: 
TLOVR OR=0.803 [0.534, 1.208]. ConClusions: This adjusted analysis of pooled 
phase 3 data of an 800mg once-daily darunavir dose showed that darunavir/cobi-
cistat has non-inferior efficacy compared with darunavir/ritonavir.
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objeCtives: Infections caused by Gram-negative bacteria, including nosocomial 
pneumonia (NP), complicated urinary tract infections (cUTI), and complicated 
intra-abdominal infections (cIAI), have been increasing. Although microbiological 
eradication is on the presumed causal path from antibiotic susceptibility to clini-
cal success, other factors impact clinical success rates as well. This study assessed 
the relationship between microbiological eradication and clinical outcomes for NP, 
cUTI, and cIAI based on randomized controlled trial (RCT) evidence. Methods: 
A systematic literature search identified RCTs (25 NP trials, 10 cUTI, 28 cIAI, and 1 
cUTI & cIAI trial) that met the following criteria: Adult patients with cUTI, cIAI, or 
NP; Gram-negative bacteria present in at least a fraction of the population; treat-
ment including coverage of Gram-negative bacteria; any measure of microbiological 
eradication and either clinical response, cure or mortality. RCTs with information on 
both eradication and clinical outcome were selected to estimate their relationship to 
